Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04755244 · ClinicalTrials.gov registry record · Phase 1
A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)
A Phase 1 study, sponsored by ALX Oncology.
- Terminated
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT04755244 is a Phase 1 study that was terminated before completion, run by ALX Oncology. The registered enrollment target is 14 participants.
The verdict
NCT04755244, a Phase 1 study, was terminated before completion, sponsored by ALX Oncology.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This Phase 1/2 clinical study will evaluate evorpacept (ALX148) in combination with venetoclax and azacitidine for the treatment of patients with acute myeloid leukemia (AML).
Interventions
- DRUG venetoclax
- DRUG azacitidine
- DRUG evorpacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2021-05-05 |
| Est. Completion | 2023-08-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04755244
The ClinicalTrials.gov registry entry for NCT04755244 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ALX Oncology, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which venetoclax is the first listed.
NCT04755244 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04755244 about?
NCT04755244 is a clinical study titled "A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)". This Phase 1/2 clinical study will evaluate evorpacept (ALX148) in combination with venetoclax and azacitidine for the treatment of patients with acute myeloid leukemia (AML).
What is the current status of trial NCT04755244?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2021-05-05. Estimated completion is 2023-08-16.
What interventions are being tested in trial NCT04755244?
The interventions under investigation include: venetoclax (DRUG), azacitidine (DRUG), evorpacept (DRUG).
Who is sponsoring clinical trial NCT04755244?
This trial is sponsored by ALX Oncology, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.